Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia

Glucagon and regulation of glucose metabolism

Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905

Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563

Minireview: The Glucagon-Like Peptides

Drucker, D. J. (2001) · Endocrinology · doi:10.1210/endo.142.2.7983 · Cited by 419

EFFECT OF EPINEPHRINE ON RAT DIAPHRAGM

Walaas, O., & Walaas, E. (1950) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56223-2 · Cited by 410

Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus1

Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368

Glucagon physiology and pathophysiology in the light of new advances

Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Conarello, S., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J. W., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 348

Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats

Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Sloop, K. W., Cao, J. X. C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20911 · Cited by 219

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

Petersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 212

Role of Liver in Pathophysiology of NIDDM

Consoli, A. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.430 · Cited by 210

Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome in db/db Mice

Liang, Y. T., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, C. A., She, P., Jetton, T. L., & Demarest, K. T. (2004) · Diabetes · doi:10.2337/diabetes.53.2.410 · Cited by 202

New approaches in the treatment of type 2 diabetes

Zhang, B. B., & Moller, D. E. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00103-4 · Cited by 196

Hyperglycemia of Diabetic Rats Decreased by a Glucagon Receptor Antagonist

Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D., & Trivedi, D. B. (1982) · Science · doi:10.1126/science.6278587 · Cited by 166

Glycemic Control in Mice with Targeted Disruption of the Glucagon Receptor Gene

Parker, J. C., Andrews, K. M., Allen, M. R., Stock, J. L., & McNeish, J. D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6265 · Cited by 160

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes

Nauck, M. A., Holst, J. J., Willms, B., & Schmiegel, W. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211750 · Cited by 145

Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats

Brand, C. L., Rolin, B., Jørgensen, P. N., Svendsen, I., Kristensen, J. S., & Holst, J. J. (1994) · Diabetologia · doi:10.1007/bf00400461 · Cited by 135

Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients

Butler, P. C., & Rizza, R. A. (1991) · Diabetes · doi:10.2337/diab.40.1.73 · Cited by 127

Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist

Unson, C. G., Gurzenda, E. M., & Merrifield, R. B. (1989) · Peptides · doi:10.1016/0196-9781(89)90010-7 · Cited by 119

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

D’Alessio, D. A., Vogel, R., Prigeon, R. L., Laschansky, E. C., Koerker, D. J., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 119

A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects

Qureshi, S. A., Candelore, M. R., Xie, D., Yang, X., Tota, L. M., Ding, V. D. H., Li, Z., Bansal, A., Miller, C. O., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 109

Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.

Larsson, H. E., & Åhrén, B. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.650 · Cited by 98

Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits

Brand, C. L., Jørgensen, P. N., Svendsen, I., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diab.45.8.1076 · Cited by 94

Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism.

Burcelin, R., Katz, E. B., & Charron, M. J. (1996) · PubMed · Cited by 93

Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

Basu, A., Alzaid, A., Dinneen, S. F., Caumo, A., Cobelli, C., & Rizza, R. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118678 · Cited by 90

Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty Rats

Fujita, Y., Kojima, H., Hidaka, H., Fujimiya, M., Kashiwagi, A., & Kikkawa, R. (1998) · Diabetologia · doi:10.1007/s001250051092 · Cited by 88

Role of glucagon in maintenance of euglycemia in fed and fasted rats

Brand, C. L., Jørgensen, P. N., Knigge, U., Warberg, J., Svendsen, I., Kristensen, J. S., & Holst, J. J. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.3.e469 · Cited by 77

Alleviation of Fatty Liver in Dairy Cows with 14-Day Intravenous Infusions of Glucagon

Hippen, A. R., She, P., Young, J. W., Beitz, D. C., Lindberg, G. L., Richardson, L. F., & Tucker, R. W. (1999) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(99)75337-3 · Cited by 60

Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists

Ling, A. L., Hong, Y., González, J., Gregor, V. E., Polinsky, A., Kuki, A., Shi, S., Teston, K., Murphy, D. E., Porter, J. W., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000547o · Cited by 42

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists

Dallas-Yang, Q., Shen, X., Strowski, M. Z., Brady, E. J., Saperstein, R., Gibson, R. E., Szalkowski, D., Qureshi, S. A., Candelore, M. R., Fenyk-Melody, J. E., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.023 · Cited by 40

Human glucagon receptor antagonists based on alkylidene hydrazides

Ling, A. L., Plewe, M. B., González, J., Madsen, P., Sams, C. K., Lau, J. F., Gregor, V. E., Murphy, D., Teston, K., Kuki, A., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00819-8 · Cited by 40

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists

Shen, D., Zhang, F., Brady, E. J., Candelore, M. R., Dallas-Yang, Q., Ding, V. D. H., Dragovic, J., Feeney, W. P., Jiang, G., McCann, P. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.101 · Cited by 40

Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats

Nakade, Y., Tsukamoto, K., Pappas, T. N., & Takahashi, T. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.090 · Cited by 37

Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists

Tine, B. A. V., Azizeh, B. Y., Trivedi, D., Phelps, J. R., Houslay, M. D., Johnson, D. G., & Hruby, V. J. (1996) · Endocrinology · doi:10.1210/endo.137.8.8754757 · Cited by 36

Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1

Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 35

Improving the Serum D-Xylose Test for the Identification of Patients With Small Intestinal Malabsorption

Ehrenpreis, E. D., Salvino, M. J., & Craig, R. M. (2001) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200107000-00009 · Cited by 20

Glucagon as a Potential Therapy for Ketosis and Fatty Liver

Hippen, A. R. (2000) · Veterinary Clinics of North America Food Animal Practice · doi:10.1016/s0749-0720(15)30105-5 · Cited by 19

Autoregulation of endogenous glucose production during hyperglucagonemia

Toft, I., Gerich, J. E., & Jenssen, T. G. (2002) · Metabolism · doi:10.1053/meta.2002.34702 · Cited by 18

Energy Metabolism in the Liver

Rui, L. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130024 · Cited by 2,401

Emerging Targets in Type 2 Diabetes and Diabetic Complications

Demir, S., Nawroth, P. P., Herzig, S., & Üstünel, B. E. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 582

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498

Hormonal regulation of hepatic glucose production in health and disease

Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429

The metabolic actions of glucagon revisited

Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406

Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models

Vuguin, P. M., & Charron, M. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01447.x · Cited by 47

ORIGINAL ARTICLE Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice

Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2013)

Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice

Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327

Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia

Rivero‐Gutiérrez, B., Haller, A. M., Holland, J., Yates, E., Khrisna, R., Habegger, K. M., DiMarchi, R. D., D’Alessio, D. A., & Pérez–Tilve, D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.012 · Cited by 24

Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes

Maharaj, A., Zhu, L., Huang, F., Qiu, H., Li, H., Zhang, C.-Y., Jin, T., & Wang, Q. (2012) · Diabetologia · doi:10.1007/s00125-012-2464-x · Cited by 8